May 18, 2021 — Stirling, U.K.-headquartered aquaculture biotechnology business Benchmark achieved higher revenues and percent earnings before interest, tax, depreciation, and amortization and impairment (adjusted EBITDA) of GBP 59.5 million (USD 84.5 million, EUR 69.2 million) and GBP 7.9 million (USD 11.2 million, EUR 9.2 million) for the six months ending on 31 March, 2021, citing a strong performance in its advanced nutrition division and solid trading in genetics and health.
Overall, the company posted a first-half operating loss of GBP 4.6 million (USD 6.5 million, EUR 5.3 million), compared with a loss of GBP 3.9 million (USD 5.5 million, EUR 4.5 million) in H1 2020.